XML 21 R10.htm IDEA: XBRL DOCUMENT v3.25.3
REVENUE
 9 Months Ended
Sep. 30, 2025
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard and Oncotype® tests. The services are considered completed upon release of a patient’s test result to the ordering healthcare provider.
The following table presents the Company’s revenues disaggregated by revenue source:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2025202420252024
Screening
Medicare Parts B & C$247,353 $201,423 $675,923 $570,550 
Commercial354,867 289,637 978,565 827,509 
Other64,020 53,841 180,240 153,246 
Total Screening666,240 544,901 1,834,728 1,551,305 
Precision Oncology
Medicare Parts B & C$50,924 $47,080 $144,732 $142,597 
Commercial50,376 47,685 146,679 143,572 
International58,784 49,433 165,628 140,688 
Other24,415 19,556 76,842 67,281 
Total Precision Oncology184,499 163,754 533,881 494,138 
Total$850,739 $708,655 $2,368,609 $2,045,443 
Screening revenue primarily includes laboratory service revenue from Cologuard and PreventionGenetics, LLC tests while Precision Oncology revenue primarily includes laboratory service revenue from global Oncotype DX and therapy selection tests.
At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. Adjustments to revenue recognized during the period relating to prior period estimates were less than 1% of revenue recorded in the Company’s condensed consolidated statement of operations for the three and nine months ended September 30, 2025 and 2024.
The Company’s deferred revenue, which is reported in other current liabilities in the Company’s condensed consolidated balance sheets, was not significant as of September 30, 2025 and December 31, 2024.
Revenue recognized for the three and nine months ended September 30, 2025 and 2024 that was included in the deferred revenue balance at the beginning of the period was not significant.